Pristimerin effectively inhibits the malignant phenotypes of uveal melanoma cells by targeting NF‑κB pathway.

@article{Zhang2017PristimerinEI,
  title={Pristimerin effectively inhibits the malignant phenotypes of uveal melanoma cells by targeting NF‑$\kappa$B pathway.},
  author={Biao Zhang and Jing Zhang and Jingxuan Pan},
  journal={International journal of oncology},
  year={2017},
  volume={51 3},
  pages={
          887-898
        }
}
Uveal melanoma (UM) is a highly aggressive intraocular malignancy that lacks any effective targeted-therapy. Neither survival nor prognosis has been improved for the past decades in patients with metastatic UM. NF‑κB pathway is reported to be abnormally activated in UM. However, the role of NF‑κB pathway as a potential therapeutical target in UM remains unclear. Here, the effect of pristimerin, a potent inhibitor of NF‑κB pathway, on UM cells in terms of growth, apoptosis, motility, invasion… 
View on PubMed
spandidos-publications.com
13 Citations
Highly Influential Citations
1
Background Citations
6
Methods Citations
1

13 Citations

Citation Type

Citation Type

Pristimerin targeting NF‐κB pathway inhibits proliferation, migration, and invasion in esophageal squamous cell carcinoma cells
TLDR
Evidence is provided for the development of pristimerin to be a new therapeutic agent for ESCC by suppressing tumour necrosis factor α (TNFα)‐induced IκBα phosphorylation, p65 translocation, and NF‐κB‐dependent gene expression.
Pristimerin‐induced uveal melanoma cell death via inhibiting PI3K/Akt/FoxO3a signalling pathway
TLDR
Findings indicate that Pristimerin may be considered as a potential chemotherapeutic agent for patients with UM and induced apoptotic cell death through inhibition of PI3K/Akt/FoxO3a pathway in UM‐1 cells.
Pristimerin enhances the effect of cisplatin by inhibiting the miR-23a/Akt/GSK3β signaling pathway and suppressing autophagy in lung cancer cells
TLDR
Western blotting revealed that Pris effectively synergized with Cis to induce cell apoptosis by inhibiting the microRNA-23a/Akt/glycogen synthase kinase 3β signaling pathway and suppressing autophagy, suggesting that this may be a potential therapeutic strategy to overcome lung cancer.
Cellular and Molecular Mechanisms of Pristimerin in Cancer Therapy: Recent Advances
TLDR
Pristimerin reverses multidrug resistance of cancer cells and exerts synergizing effects with other chemotherapeutic drugs and multi-targeted biological and molecular regulations in cancers.
MicroRNA-29a Inhibits Growth, Migration and Invasion of Melanoma A375 Cells in Vitro by Directly Targeting BMI1
Background/Aims: Melanoma is one of the most aggressive malignant tumors, with increasing incidence, poor prognosis, and lack of any effective targeted therapies. Abnormal expression of miR-29a has…
Synergistic anti-cancer effect of pristimerin and docetaxel on human colorectal HCT-116 cells
Aldehyde dehydrogenase-positive melanoma stem cells in tumorigenesis, drug resistance and anti-neoplastic immunotherapy
TLDR
In vivo and in vitro studies that illustrate the relationship between aldehyde dehydrogenase and MICs are summarized, rendering ALDH a potential marker to evaluate the efficacy of anti-neoplastic therapies or an adjuvant anti-melanoma target.
Clinicopathological relevance of NFκB1/p50 nuclear immunoreactivity and its relationship with the inflammatory environment of uveal melanoma.
Triptolide ameliorates fine particulate matter-induced podocytes injury via regulating NF-κB signaling pathway
TLDR
It is suggested that triptolide could prevent against PM2.5-induced podocytes injury via suppressing NF-κB signaling pathway.
Identification of differentially expressed genes and functional annotations associated with metastases of the uveal melanoma
TLDR
It is suggested that SCD5, SPTBN1, FABP5, SQLE, PTPLA, and CDC25B transcription levels were of high prognostic value, which might assist to understand the underlying carcinogenesis or advancement of UVM better.
...
1
2
...

References

SHOWING 1-10 OF 46 REFERENCES
Verteporfin induces apoptosis and eliminates cancer stem-like cells in uveal melanoma in the absence of light activation.
TLDR
This study demonstrated the anti-neoplastic activity of verteporfin against UM cells in vitro, providing a rationale for evaluating this agent in clinical investigation.
Class III-specific HDAC inhibitor Tenovin-6 induces apoptosis, suppresses migration and eliminates cancer stem cells in uveal melanoma
TLDR
In conclusion, the findings suggest that Tenovin-6 may be a promising agent to kill UM bulk tumor cells and CSCs.
Pristimerin inhibits proliferation, migration and invasion, and induces apoptosis in HCT-116 colorectal cancer cells.
Pristimerin triggers AIF-dependent programmed necrosis in glioma cells via activation of JNK.
Pristimerin overcomes adriamycin resistance in breast cancer cells through suppressing Akt signaling.
TLDR
It is demonstrated that pristimerin indeed displayed potent cytocidal effect on multidrug-resistant MCF-7/ADR breast cancer cells, and that these effects occurred through the suppression of Akt signaling, which in turn led to the downregulation of antiapoptotic effectors and increased apoptosis.
Pristimerin demonstrates anticancer potential in colorectal cancer cells by inducing G1 phase arrest and apoptosis and suppressing various pro-survival signaling proteins.
TLDR
The results suggest that pristimerin may have potential as a new targeting therapeutic strategy for the treatment of colon cancer, and examined the different signaling pathways affected by its action in three colon cancer cell lines.
Targeting NF-κB signaling pathway suppresses tumor growth, angiogenesis, and metastasis of human esophageal cancer
TLDR
Exposure of ESCC cells to two NF-κB inhibitors, Bay11-7082 and sulfasalazine, not only reduced cancer cell proliferation, but also induced apoptosis and enhanced sensitivity to chemotherapeutic drugs, 5-fluorouracil, and cisplatin.
Targeting NF-κB for colorectal cancer
TLDR
Evidence for the participation of activated NF-κB in carcinogenesis is discussed and the possibility of NF-σB being a target for CRC treatment is considered, as well as the need to examine anti-NF-κBs for use as a therapy target.
The NFκB pathway: a therapeutic target in glioblastoma
TLDR
appropriate control of NFκB activity, which can be achieved by gene modification or pharmacological strategies, would provide a potential approach for the management ofNFκB related tumors, including glioblastoma.
Pristimerin inhibits angiogenesis in adjuvant-induced arthritic rats by suppressing VEGFR2 signaling pathways.
...
1
2
3
4
5
...